



Clinical trial results:

AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Summary

EudraCT number	2008-006955-28
Trial protocol	DE NL SE AT ES GB IT
Global end of trial date	10 October 2013

Results information

Result version number	v1 (current)
This version publication date	24 July 2016
First version publication date	24 July 2016

Trial information

Trial identification

Sponsor protocol code	C08-003B
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00844428
WHO universal trial number (UTN)	-
Other trial identifiers	BB-IND 11075: BB-IND 11075

Notes:

Sponsors

Sponsor organisation name	Alexion Pharmaceuticals Incorporated
Sponsor organisation address	352 Knotter Drive, Cheshire, CT, United States, 06410
Public contact	European Clinical Trial Information, Alexion Europe SAS, +33 1 47 10 06 06, clinicaltrials.eu@alxn.com
Scientific contact	European Clinical Trial Information, Alexion Europe SAS, +33 1 47 10 06 06, clinicaltrials.eu@alxn.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 December 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 October 2013
Global end of trial reached?	Yes
Global end of trial date	10 October 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the effect of eculizumab on TMA-Event Free status defined as the absence for at least 12 weeks of [1] decrease in platelet count of >25% from the Platelet Count Pre-PT Baseline Set-Point; [2] PT while the patient is receiving eculizumab, or [3] new dialysis

Protection of trial subjects:

Vaccination against N. meningitidis at least 14 days prior to study drug initiation or prophylactic antibiotics protection until 2 weeks after vaccination

Background therapy: -

Evidence for comparator:

Each patient served as his/her own control

Actual start date of recruitment	24 July 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	France: 9
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Sweden: 1
Worldwide total number of subjects	20
EEA total number of subjects	18

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	5
Adults (18-64 years)	15
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Results from Study C08-003A were combined with results from another study, Study C08-003B. Study C08-003A was conducted in adults (n=15) and Study C08-003B was conducted in adolescents (n=5; EudraCT No.: 2008-006955-28). Combined results from these 2 studies are reported here.

Pre-assignment

Screening details:

Patients receiving PT for aHUS and observed to receive ≥ 1 PT every two weeks, and no more than 3 PT treatments/week for at least 8 weeks before the first dose of eculizumab. Patients who met the eligibility criteria during the Observation Period were enrolled into the Treatment Period which commenced with the first eculizumab dose.

Pre-assignment period milestones

Number of subjects started	23 ^[1]
Number of subjects completed	20

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screen failure: 3
----------------------------	-------------------

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Period 1 is the observation period during which baseline is assessed.

Period 1

Period 1 title	Observation Period (8 Weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Observation
-----------	-------------

Arm description:

During the 8-week Observation Period, clinical laboratory testing, platelet counts, hemolytic markers, pro-thrombotic measures, pro-inflammatory markers, complement markers, and samples for renal function measures were collected on a weekly basis. Adverse events were also recorded on a weekly basis during the 8-week Observation Period. Additionally, all PT sessions administered to the patient during the Observation Period were recorded

Arm type	No intervention
----------	-----------------

No investigational medicinal product assigned in this arm

Number of subjects in period 1	Observation
Started	20
Completed	20

Period 2

Period 2 title	Treatment Period (26 Weeks)
Is this the baseline period?	Yes ^[2]
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	eculizumab
------------------	------------

Arm description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 20 patients who were treated with study drug were included in the ITT population.

Arm type	Experimental
Investigational medicinal product name	eculizumab
Investigational medicinal product code	eculizumab
Other name	SOLiris
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later
Maintenance dose - 1200 mg every two weeks

Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

Notes:

[2] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: The post-treatment period only applies to the patients who discontinued treatment. There are 5 patients who were off drug at end of study.

Number of subjects in period 2	eculizumab
Started	20
Completed	20

Period 3

Period 3 title	Extension Treatment Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	long-term eculizumab
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	eculizumab
Investigational medicinal product code	eculizumab
Other name	Soliris
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later

Maintenance dose - 1200 mg every two weeks

Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

Number of subjects in period 3 ^[3]	long-term eculizumab
Started	19
Completed	18
Not completed	1
Death	1

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: All analyses summarize results from pooled data of 2 protocols: C08-003A and C08-003B. One adolescent patient (from study C08-003B) discontinued from the study after 26 weeks.

Period 4

Period 4 title	Post-treatment period (discontinuation)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	eculizumab
Arm description:	
Patients who discontinued eculizumab during the study were required to have follow-up visits. These assessments were performed at 1 week, 2 weeks, 4 weeks, and 8 weeks after the last dose of eculizumab.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 4^[4]	eculizumab
Started	5
Completed	4
Not completed	1
Adverse event, serious fatal	1

Notes:

[4] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The worldwide number enrolled in the trial do not include screen failure.

Baseline characteristics

Reporting groups

Reporting group title	eculizumab
-----------------------	------------

Reporting group description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 20 patients who were treated with study drug were included in the ITT population.

Reporting group values	eculizumab	Total	
Number of subjects	20	20	
Age categorical Units: Subjects			
Adolescents (12-17 years)	5	5	
Adults (18-64 years)	15	15	
Age continuous Units: years			
arithmetic mean	32.3		
standard deviation	± 14.92	-	
Gender categorical Units: Subjects			
Female	12	12	
Male	8	8	
Race Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	2	2	
White	18	18	
More than one race	0	0	
Unknown or Not Reported	0	0	
Platelet Category Units: Subjects			
< 150 x10 ⁹ /L	3	3	
≥ 150 x10 ⁹ /L	17	17	
LDH Category Units: Subjects			
> ULN	4	4	
≤ ULN	16	16	
eGFR category Units: Subjects			
< 15	4	4	
15 ≤ 30	6	6	

30 ≤ 45	6	6	
45 ≤ 60	2	2	
60 ≤ 90	2	2	
CKD Units: Subjects			
Stage 2	2	2	
Stage 3a	2	2	
Stage 3b	6	6	
Stage 4	6	6	
Stage 5	4	4	
Platelet Count Units: x10 ⁹ /L			
arithmetic mean	227.98		
standard deviation	± 77.658	-	
LDH Units: U/l			
arithmetic mean	222.6		
standard deviation	± 69.88	-	
Creatinine Units: micromole(s)/litre			
arithmetic mean	286.9		
standard deviation	± 215.44	-	
eGFR Units: mL/min/1.73*m ²			
arithmetic mean	30.9		
standard deviation	± 19.01	-	

End points

End points reporting groups

Reporting group title	Observation
-----------------------	-------------

Reporting group description:

During the 8-week Observation Period, clinical laboratory testing, platelet counts, hemolytic markers, pro-thrombotic measures, pro-inflammatory markers, complement markers, and samples for renal function measures were collected on a weekly basis. Adverse events were also recorded on a weekly basis during the 8-week Observation Period. Additionally, all PT sessions administered to the patient during the Observation Period were recorded

Reporting group title	eculizumab
-----------------------	------------

Reporting group description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 20 patients who were treated with study drug were included in the ITT population.

Reporting group title	long-term eculizumab
-----------------------	----------------------

Reporting group description: -

Reporting group title	eculizumab
-----------------------	------------

Reporting group description:

Patients who discontinued eculizumab during the study were required to have follow-up visits. These assessments were performed at 1 week, 2 weeks, 4 weeks, and 8 weeks after the last dose of eculizumab.

Primary: Proportion of Patients With TMA Event-free Status

End point title	Proportion of Patients With TMA Event-free Status ^[1]
-----------------	--

End point description:

TMA Event-free status is defined as the absence for at least 12 weeks of [1] decrease in platelet count of > 25% from the Platelet Count Pre-PT Baseline Set Point; [2] PT while the patient is receiving eculizumab, and [3] new dialysis.

End point type	Primary
----------------	---------

End point timeframe:

Through 26 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study is a single arm trial and the system does not support statistical analyses for single arm trial.

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	80 (56 to 94)			

Statistical analyses

No statistical analyses for this end point

Primary: Proportion of Patients With Hematologic Normalization

End point title	Proportion of Patients With Hematologic Normalization ^[2]
-----------------	--

End point description:

Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.

End point type	Primary
----------------	---------

End point timeframe:

Through 26 weeks

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study is a single arm trial and the system does not support statistical analyses for single arm trial.

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	90 (68 to 99)			

Statistical analyses

No statistical analyses for this end point

Primary: Proportion of Patients With Complete TMA Response

End point title	Proportion of Patients With Complete TMA Response ^[3]
-----------------	--

End point description:

The proportion of patients who achieved a Complete TMA Response from baseline through 26 weeks of treatment with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as $\geq 25\%$ reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

End point type	Primary
----------------	---------

End point timeframe:

Through 26 weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study is a single arm trial and the system does not support statistical analyses for single arm trial.

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	25 (9 to 49)			

Statistical analyses

No statistical analyses for this end point

Secondary: TMA Intervention Rate

End point title	TMA Intervention Rate
-----------------	-----------------------

End point description:

TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through 26 weeks) for PE/PI and (from the fifteenth day following the first eculizumab dose through 26 weeks) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

End point type	Secondary
----------------	-----------

End point timeframe:

Through 26 weeks

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: #events/patient/day				
arithmetic mean (standard deviation)	0 (\pm 0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Platelet Count Change From Baseline to 26 Weeks

End point title	Platelet Count Change From Baseline to 26 Weeks
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to 26 Weeks

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: 10 ⁹ cells/L				
least squares mean (confidence interval 95%)	6.75 (-15.73 to 29.23)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Patients With Platelet Count Normalization

End point title	Proportion of Patients With Platelet Count Normalization
End point description: Platelet count normalization was defined as the platelet count observed to be $\geq 150 \times 10^9/L$ on at least 2 consecutive measurements which span a period of at least 4 weeks.	
End point type	Secondary
End point timeframe: Through 26 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	90 (68 to 99)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Patients With TMA Event-free Status

End point title	Proportion of Patients With TMA Event-free Status
End point description: TMA Event-free status is defined as the absence for at least 12 weeks of [1] decrease in platelet count of > 25% from the Platelet Count Pre-PT Baseline Set Point; [2] PT while the patient is receiving eculizumab, and [3] new dialysis.	
End point type	Secondary
End point timeframe: Through End of Study, Median Exposure 156 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	95 (75 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Patients With Hematologic Normalization

End point title	Proportion of Patients With Hematologic Normalization
End point description: Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.	
End point type	Secondary
End point timeframe: Through End of Study, Median Exposure 156 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	90 (68 to 99)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Patients With Complete TMA Response

End point title	Proportion of Patients With Complete TMA Response
End point description: The proportion of patients who achieved a Complete TMA Response from baseline through end of study with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as $\geq 25\%$ reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.	
End point type	Secondary
End point timeframe: Through End of Study, Median Exposure 156 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	55 (32 to 77)			

Statistical analyses

No statistical analyses for this end point

Secondary: TMA Intervention Rate

End point title	TMA Intervention Rate
End point description: TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through end of study) for PE/PI and (from the 15th day following the first eculizumab dose through end of study) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.	
End point type	Secondary
End point timeframe: Through End of Study, Median Exposure 156 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: #events/patient/day				
arithmetic mean (standard deviation)	0 (± 0.02)			

Statistical analyses

No statistical analyses for this end point

Secondary: Platelet Count Change From Baseline to 156 Weeks

End point title	Platelet Count Change From Baseline to 156 Weeks
End point description:	
End point type	Secondary
End point timeframe: From Baseline to 156 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: 10 ⁹ cells/L				
least squares mean (confidence interval 95%)	-3.68 (-25.15 to 17.79)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Patients With Platelet Count Normalization

End point title	Proportion of Patients With Platelet Count Normalization
End point description: Platelet count normalization was defined as the platelet count observed to be $\geq 150 \times 10^9/L$ on at least 2 consecutive measurements which span a period of at least 4 weeks.	
End point type	Secondary
End point timeframe: Through End of Study, Median Exposure 156 Weeks	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of Participants				
number (confidence interval 95%)	90 (68 to 99)			

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration

End point title	Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration
End point description: PK parameters C _{min} and C _{max} were estimated using a population PK model developed from the observed PK concentration data.	
End point type	Secondary
End point timeframe: Induction Phase for 4 weeks followed by Maintenance Phase starting on Week 5 through 26 weeks or longer.	

End point values	eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: microgram(s)/millilitre				
arithmetic mean (standard deviation)				
max concentration during induction period	161.47 (± 27.29)			
max concentration during maintenance	427.48 (± 67.54)			
min concentration during induction period	112.43 (± 16.98)			
min concentration during maintenance	212.45 (± 53.75)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Through end of study; Exposure to eculizumab in this study extended for a median of 156 weeks and ranged from 26 weeks to 182 weeks.

Adverse event reporting additional description:

At every visit, patients were asked a standard non-leading question to elicit any changes in their medical well-being including inquiry about any hospitalization, accidents, and new or changed concomitant medication regimens. AEs were also documented from any data collected (e.g. laboratory values, physical examination findings, ECG changes, etc.).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

Reporting groups

Reporting group title	eculizumab
-----------------------	------------

Reporting group description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

Serious adverse events	eculizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 20 (65.00%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal cell carcinoma			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vein disorder			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis limb			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Catheter removal			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Limb operation			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Medical device complication			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Transplant rejection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Amyloidosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Electrocardiogram T wave inversion			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tendon rupture			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Pericardial effusion			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Impaired gastric emptying			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure chronic			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bacteraemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile colitis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enterococcal infection			

subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis norovirus				
subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatitis E				
subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Localised infection				
subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peritonitis				
subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	2 / 20 (10.00%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Post procedural infection				
subjects affected / exposed	1 / 20 (5.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				

subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Q fever			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	eculizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 20 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Angiomyolipoma			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Benign breast neoplasm			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Lipoma			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Melanocytic naevus			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Skin papilloma			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Squamous cell carcinoma			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Vascular disorders			
Arterial haemorrhage			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Arterial occlusive disease			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Haematoma			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Haemorrhage			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	9 / 20 (45.00%)		
occurrences (all)	9		
Hypotension			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Orthostatic hypotension			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Vein disorder			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Venous thrombosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Surgical and medical procedures			
Arteriovenous fistula operation			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hip arthroplasty			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Chest pain			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Extravasation			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Hypothermia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Infusion site extravasation			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Infusion site swelling			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Injection site haematoma			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Localised oedema			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Medical device complication			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Oedema			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		

Oedema peripheral subjects affected / exposed occurrences (all)	6 / 20 (30.00%) 6		
Pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Polyp subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Pyrexia subjects affected / exposed occurrences (all)	7 / 20 (35.00%) 7		
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 4		
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Reproductive system and breast disorders Breast swelling subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Menorrhagia subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Oedema genital subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Ovarian cyst subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	7 / 20 (35.00%) 7		

Dyspnoea			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Epistaxis			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Lung consolidation			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Nasal congestion			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Oropharyngeal pain			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Productive cough			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Pulmonary congestion			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Upper respiratory tract congestion			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Anxiety			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Depression			

subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Insomnia			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Investigations			
Basophil count increased			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Blood creatine increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Blood creatinine increased			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Blood parathyroid hormone increased			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Blood potassium increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Blood pressure abnormal			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Cardiac murmur			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Electrocardiogram T wave inversion			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Eosinophil count increased			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Glomerular filtration rate decreased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Haptoglobin increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Low density lipoprotein increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Monocyte count increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Platelet count decreased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Reticulocyte count increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
White blood cell count increased			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
White blood cells urine positive			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Arteriovenous fistula site complication			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Contusion			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Corneal abrasion			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Excoriation			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Foreign body			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Head injury			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Hip fracture			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Humerus fracture			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Ligament sprain			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Limb injury			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Scratch			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Wound			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Wrist fracture			

subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Congenital, familial and genetic disorders Dermoid cyst subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Cardiac disorders Hypertensive heart disease subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Nervous system disorders Cerebral haematoma subjects affected / exposed occurrences (all) Cerebral microangiopathy subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all) Myoclonus subjects affected / exposed occurrences (all) Neuropathy peripheral subjects affected / exposed occurrences (all) Paraesthesia subjects affected / exposed occurrences (all) Paresis subjects affected / exposed occurrences (all) Somnolence	1 / 20 (5.00%) 1 1 / 20 (5.00%) 1 3 / 20 (15.00%) 3 11 / 20 (55.00%) 11 1 / 20 (5.00%) 1 1 / 20 (5.00%) 1 1 / 20 (5.00%) 1 1 / 20 (5.00%) 1		

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Blood and lymphatic system disorders			
Abnormal clotting factor			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Anaemia folate deficiency			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Anaemia			
subjects affected / exposed	7 / 20 (35.00%)		
occurrences (all)	7		
Iron deficiency anaemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Leukopenia			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Lymph node pain			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Lymphadenopathy			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Lymphopenia			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Microcytosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Splenomegaly			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		

Neutropenia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Ear and labyrinth disorders Deafness bilateral subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Ear pain subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Motion sickness subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Tinnitus subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Vertigo subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 4		
Eye disorders Eye irritation Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Ocular hyperaemia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	5 / 20 (25.00%) 5		

Abdominal pain upper subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Abdominal pain lower subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Abdominal rigidity subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Aphthous stomatitis subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3		
Ascites subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Constipation subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3		
Crohn's disease subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Diarrhoea subjects affected / exposed occurrences (all)	10 / 20 (50.00%) 10		
Flatulence subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Gingival bleeding subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Gingival hyperplasia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Gingival ulceration subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		

Haemorrhoids			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Impaired gastric emptying			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	2		
Malaena			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	10 / 20 (50.00%)		
occurrences (all)	10		
Subileus			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Tooth impacted			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Umbilical hernia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	10 / 20 (50.00%)		
occurrences (all)	10		
Medical device pain			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Chest discomfort			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hepatocellular injury			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Blister			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Dermatitis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Ecchymosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Eczema			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Erythema			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Heat rash			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hyperhidrosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Psoriasis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		

Rash macular subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Skin disorder subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Skin fissures subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Haematuria subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 2		
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Pollakiuria subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Proteinuria subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Renal failure subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Renal impairment subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3		
Renal failure acute subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Endocrine disorders			

Adrenal insufficiency subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3		
Back pain subjects affected / exposed occurrences (all)	6 / 20 (30.00%) 6		
Bone pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Flank pain subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Groin pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Joint swelling subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Muscle spasms subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 4		
Muscular weakness subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Myalgia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Neck pain			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Osteoporosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	4 / 20 (20.00%)		
occurrences (all)	4		
Tendon disorder			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Tendonitis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Infections and infestations			
Ateriovenous fistula site infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
BK virus infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Bacteraemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	2		
Bronchitis			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Cytomegalovirus infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Erythrasma			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Escherichia urinary tract infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		

Fungal infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Fungal skin infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Herpes zoster			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		
Infection			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Influenza			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	2		
Localised infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	12 / 20 (60.00%)		
occurrences (all)	12		
Otitis media			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Pneumonia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	2		
Post procedural infection			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	3 / 20 (15.00%)		
occurrences (all)	3		

Upper respiratory tract infection subjects affected / exposed occurrences (all)	8 / 20 (40.00%) 8		
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3		
Vaginal infection subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Viral pharyngitis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Metabolism and nutrition disorders			
Acidosis subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Alkalosis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Cachexia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Decreased appetite subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Dehydration subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Fluid overload			

subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hypercalcaemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hyperkalaemia			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Hyponatraemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Malnutrition			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Metabolic acidosis			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Vitamin D deficiency			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hyperglycaemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hyperuricaemia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
Hypokalaemia			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Musculoskeletal pain			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 September 2009	Global modification to clinical study protocol, in particular, to: <ul style="list-style-type: none">- provide a justification for the selected dosing regimen in aHUS as compared to the experience with eculizumab in PNH- correct the eculizumab dose prior to any FFP intervention based on modeling data- update certain entry criteria by adding wash out periods instead of total exclusion based on current standards of care- introduce antibiotic coverage for patients that are post transplant and on immunosuppressive treatment and/or aggressive plasma therapy- align protocol with European Summary of Product Characteristics, in particular requirements pertaining to contraception methods and hypersensitivity to eculizumab, murine proteins or to excipients- define the extension period to allow patients to continue to receive the investigational product while pending access to licensed product
01 September 2010	Global change to the clinical trial protocol to make some clarifications with regards to the ADAMTS13 activity exclusion cut-off value, and intended statistical tests.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/23738544>